Pernicious anemia (PA) is a chronic condition that is usually treated using B(12) injections. Due to the pandemic, many patients were prescribed an alternative oral B(12) treatment. There is limited evidence that this is effective at managing symptoms of PA. The aim of this study was to document treatment changes across the United Kingdom and the impact on patient experience. An online survey explored how the treatment of PA has been managed during the early stages of the pandemic; responses were analyzed for a subsample of participants receiving prescribed B(12) injections and where changes in treatment applied (n = 329) using content analysis. The most common reported change was the suspension of injections, with oral B(12) being offered as an alternative treatment. Patients were concerned about the long-term impact that changes would have on their condition management, and many stated that they were dissatisfied with the level of care received. Those who were supported by health care providers to continue their usual treatment reported experiencing improved health and well-being. This study highlights the major impact of treatment changes on patient health outcomes and the need to further support health care professionals with PA management during and beyond the pandemic.
How Do Patients Receiving Prescribed B(12) Injections for the Treatment of PA Perceive Changes in Treatment During the COVID-19 Pandemic? A UK-Based Survey Study